The FDA OKs generic Daraprim, the Martin Shkreli therapy that triggered an unending tempest over drug pricing
The FDA posted a new generic drug approval Friday afternoon, and this one arrived with a little extra relish added to the customary pronouncement.
The agency has given Cerovene the green light to sell generic Daraprim, Martin Shkreli’s treatment for toxoplasmosis that detonated a world class brouhaha over drug pricing that has tainted the industry. Shkreli no sooner acquired the old, once cheap drug than he instantly raised the price by more than 5,000%, something that the general public — and a big segment of the biopharma industry — was profoundly appalled by.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.